Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sanofi-Aventis Acomplia Phase III obesity data

Sanofi-Aventis (Euronext: SAN; SNY) said one-year data from the U.S. and European double-blind two-year

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE